Trial Profile
Efficacy of Re188-P2045 in imaging and treating lung cancer patients who over-express somatostatin receptors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2017
Price :
$35
*
At a glance
- Drugs Rhenium 188 P 2045 (Primary)
- Indications Lung cancer
- Focus Diagnostic use; Therapeutic Use
- 05 Jul 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology